MedTrace Logo

HPC Offered for PRESERVE Expansion

NCT07145411 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2025-08-28

No results posted yet for this study

Summary

Ossium recognizes that not all patients who could benefit from Ossium's HPC, Marrow can access the PRESERVE trial for logistical or eligibility reasons. The HOPE program is expanded access program to serve these patients by providing our bone marrow product

Conditions

  • Bone Marrow Transplant (BMT)

Interventions

OTHER

Bone Marrow Transplant with Ossium's HPC, Marrow (bone marrow recovered from deceased organ and tissue donors)

The HOPE Program does not include any investigational drugs. The medicines and procedures in this program are standard of care for a transplant. Bone marrow cells from a deceased organ and tissue donor for use in your transplant is the only product offered to you by Ossium Health.

Sponsors & Collaborators

  • Ossium Health, Inc.

    lead INDUSTRY

Eligibility

Min Age
12 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-27
Primary Completion
2027-08-31
Completion
2029-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07145411 on ClinicalTrials.gov